Lilly's experimental drug outperforms Zepbound in weight-loss trial
Eli Lilly's experimental combination weight-loss drug showed superior results compared to its own blockbuster Zepbound in a head-to-head trial, increasing competition with Novo Nordisk for obesity therapies.
Story updates
02:15:36 PM UTC
SquawkNews
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
02:16:13 PM UTC
SquawkNews
Eli Lilly and Company said EloraTZP, a combo of eloralintide and tirzepatide, produced greater weight loss and A1C reduction than tirzepatide 15 mg in adults with obesity and type 2 diabetes.Material DetailsContext by AI AnalystThis is an early-to-mid stage clinical signal building on Lilly’s incre…
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, sharpening competition with Danish rival Novo Nordisk for newer obesity treatments.